在寻找心房动的驱动器
Lianne N van Staveren1, Yannick J H J Taverne2, Richard Hendriks3
1Department of Cardiology, Erasmus Medical Center, Rotterdam.
Heart rhythm
|May 21, 2025
概括
短期心房动周期长度 (AFCLs) 与导电阻和光滑波传播有关,而不是焦点驱动因素. 识别最快或最常规的部位并不能确定心房的驱动因素.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 绘制心脏地图是指绘制心脏地图.
背景情况:
- 短期心房动周期长度 (AFCLs) 和定期的激活模式与心房动驱动因素有关.
- 之前的研究依赖于自动电图评估来确定动率.
研究的目的:
- 研究AFCL之间的关系,它的时间变化,和驾驶员类型的激活模式.
- 使用高密度本地激活时间映射进行详细分析.
主要方法:
- 在71名心脏外科手术患者中进行了高密度心表图绘制.
- 识别了具有最短AFCL中位数和最小AFCL标准偏差的记录站点.
- 分析了激活模式,包括焦点,旋转,平滑传播,导电阻 (CB),碰撞和残留活动.
主要成果:
- 最短的中位数AFCL位点显示出更多的导电阻 (CB) 和分数潜力.
- 最小的AFCL标准偏差点表现出更平稳的波传播和更多的单个电位.
- 最快或最常规的激活部位并没有产生重复的焦点动波.
结论:
- 最快或最常规的心房区域具有导电阻和光滑波,而不是重复的焦点/旋转模式.
- 这项研究驳斥了通过最快或最常规的激活站点来识别司机的概念.
相关概念视频
Disturbances in Heart Rhythm
812
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
812
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
879
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
879
Mechanism of Cardiac Arrhythmias
867
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
867
Anticoagulant Drugs: Low-Molecular-Weight Heparins
586
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
586
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
746
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
746
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K


